Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0786
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2613
    -0.0009 (-0.07%)
     
  • USD/JPY

    151.3000
    -0.0720 (-0.05%)
     
  • Bitcoin USD

    69,999.74
    -582.75 (-0.83%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Pfizer laments narrow recommendation for meningitis vaccine

Feb 26 (Reuters) - An advisory committee to the U.S. Centers for Disease Control and Prevention (CDC) has recommended that people aged 10 to 25 at increased risk of meningitis be vaccinated against the bacteria, Pfizer Inc said on Thursday.

But the largest U.S. drugmaker, whose Trumenba meningitis vaccine was approved in October for the same age group, said it was disappointed that the CDC advisory panel did not vote to recommend broader usage of its new vaccine.

(Reporting by Ransdell Pierson; Editing by Alan Crosby)

Advertisement